Flotation mass-spectra and negative surface potential of low density lipoprotein particles of hyperlipidemic patients after emergency abolishing for lavostatin treatment
The lipid status of lovastatin-treated hyperlipidemic patients with documented atherosclerosis of coronary arteries and carotid artery atheroma without signs of calcinosis significantly changed 4 weeks after termination of lovastatin therapy. LDL flotation mass-spectra were shown to be a sensitive indicator of variations of the lipid status. All LDL mass-spectra can be subdivided into four subfractions (from 12 to 32 S at solvent density of 1.170 g/ml and a step of 5 S). Taking into consideration previous data on total electronegative charge of LDL subfractions flotation mass-spectra indicate that lovastatin caused reduction of total negative surface charge of LDL by 1.8-fold mainly due to reduction of (17-22) and (22-27) S. However, in patients with high level of triglycerols reduction of LDL electronegative charge was due to decrease of cholesterol in (17-22) S subfraction. The latter consists of the smallest particles of the highest density. Combined analysis of similarity in lipid parameters and flotation mass-spectra of LDL allows recognizing rather homogenous groups of patients demonstrating similar responsiveness to lovastatin therapy.
Download PDF:
Citation:
Morozkin A.D., Soumarokov A.B., Medvedeva N.V., Lyakishev A.A. (2003) Flotation mass-spectra and negative surface potential of low density lipoprotein particles of hyperlipidemic patients after emergency abolishing for lavostatin treatment. Biomeditsinskaya Khimiya, 49(6), 566-575.
Morozkin A.D. et al. Flotation mass-spectra and negative surface potential of low density lipoprotein particles of hyperlipidemic patients after emergency abolishing for lavostatin treatment // Biomeditsinskaya Khimiya. - 2003. - V. 49. -N 6. - P. 566-575.
Morozkin A.D. et al., "Flotation mass-spectra and negative surface potential of low density lipoprotein particles of hyperlipidemic patients after emergency abolishing for lavostatin treatment." Biomeditsinskaya Khimiya 49.6 (2003): 566-575.
Morozkin, A. D., Soumarokov, A. B., Medvedeva, N. V., Lyakishev, A. A. (2003). Flotation mass-spectra and negative surface potential of low density lipoprotein particles of hyperlipidemic patients after emergency abolishing for lavostatin treatment. Biomeditsinskaya Khimiya, 49(6), 566-575.
References
Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial Results: parts I and II (1984) J. Am.Med.Assoc, 251, 351 - 374. Scholar google search
Lindgren F.T., Jensen L.C., Hatch F.T. (1972) In: Blood Lipids and Lipoproteins: Quantitation, composition and metabolism, N.Y., John Wiley and Sons. pp. 181- 274. Scholar google search
